A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
NCT03969134
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
86
Enrollment
OTHER
Sponsor class
Conditions
Leishmaniasis, Cutaneous
Interventions
BIOLOGICAL:
ChAd63-KH
OTHER:
Placebo
Sponsor
University of York